ArticleNature communications2025
Optically tunable catalytic cancer therapy using enzyme-like chiral plasmonic nanoparticles.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Plasmonically Reinforced Self-Sufficient Nanozymes Dysregulating Redox Homeostasis for Augmented Cascade Catalytic Oncotherapy.Advanced healthcare materials · 2026Article
- Four in One: Parallel Determination of Optical Activity and Optical Anisotropy from Single Plasmonic Nanostructures.ACS nano · 2026Article
- Nanozymes in Tumor Microenvironment Modulation for Cancer Therapy.Biomaterials research · 2026Review
- All Nanozyme-Based Cascade Reactions for Biomedical Applications: from Self-Cascading Nanozyme to Immobilized Cascade Nanozyme.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Stimuli-responsive hydrogels based on cascade reactions: a novel strategy to promote the efficient repair of diabetic wounds.Theranostics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Cascade enzymatic reactions in living organisms are fundamental reaction mechanisms in coordinating various complex biochemical processes such as metabolism, signal transduction, and gene regulation. Many studies have attempted to mimic cascade reactions using nanoparticles with enzyme-like activity; however, precisely tuning each reaction within complex networks to enhance the catalytic activity remains challenging. Here, we present enzyme-like chiral plasmonic nanoparticles for optically tunable catalytic cancer therapy. We create chiral plasmonic nanoparticles with glucose oxidase (GOD) and peroxidase (POD) activities, followed by introducing circularly polarized light (CPL). By sequentially activating GOD and POD reactions with right-handed CPL (RC) followed by left-handed CPL (LC), we achieve 1.25- and 1.9-fold enhanced catalytic performance (overall 1.3 times enhancement) compared to non-controlled cascade reactions by creating an optimal acidic environment for the subsequent reaction. Moreover, the D-Au nanoparticle shows a 2-fold higher binding selectivity to D-glucose substrates, attributed to chirality matching. In both cell studies and male mouse models, sequentially irradiated groups (RC followed by LC) exhibit the highest radical generation and the most efficient treatment outcomes compared to the other systems under different irradiation conditions. We believe that our system holds strong potential for medical applications, suggesting a promising platform for catalytic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.